International: +1-347-960-6455
Various Advancements in the Drug Development Technologies are Beholding the Growth of Presbyopia Therapeutics Pipeline

According to a new research report “Presbyopia Therapeutics – Pipeline Analysis 2019, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments” published by Pharma Proff, presbyopia therapeutics currently exhibits a proliferating pipeline with 10+ therapeutic candidates.

Presbyopia Therapeutics Pipeline Insights

Presbyopia is an age-related eye disorder, which affects the near sight vision. Primary cause of the disease is loss of flexibility of eye lenses present in cornea. Due to this, patients face difficulty in day-to-day activities like reading, blurred vision, headaches, and eyestrain. Side-effects of drugs such as diuretics, anti-depressants, and anti-histamines can also lead to the occurrence of presbyopia. Additionally, diseases, such as diabetes, cardiovascular diseases, and multiple sclerosis, also tend to cause presbyopia.

Presbyopia can be diagnosed through a general refraction assessment with the help of dilation. Moreover, due to unavailability of approved therapies in the market, use of eyeglasses, contact lenses, and surgery can treat presbyopia. Among these, eyeglasses and contact lenses are most frequently used for the management of various types of ophthalmic disorders including presbyopia.

Insights into Pipeline Segments

According to the research, most of pipeline therapeutic drug candidates are being developed for topical administration. It is observed that the topical administration is the most effective method of treatment. It is easy to use, non-invasive, and ensures high level of patient satisfaction.

Positive Clinical Trial Results are Expected to Drive Presbyopia Therapeutics Pipeline

Companies that are developing therapeutics for presbyopia have shown positive clinical results in various phases of drug development. For instance, in July 2018, Presbyopia Therapies LLC reported that its topical PRX ophthalmic solution met primary efficacy and safety endpoints in a phase IIb study. Similarly, in May 2016, Encore Vision Inc. (now acquired by Novartis International AG) announced phase I/II study positive results of EV06 ophthalmic solution. This drug candidate is first-in-class, being targeted for softening of stiffened lenses.

Browse Detailed Report at:

Strategic Advancements Play a Pivotal Role in the Presbyopia Therapeutics Development

In the wake of strategic development activities, company like Novartis International AG acquired Encore Vision to expand its portfolio of topical treatment candidate of presbyopia.

Some of the key players involved in the development of drugs for presbyopia are Novartis International AG, Presbyopia Therapies LLC, ViewPoint Therapeutics Inc., Allergan plc, Cellix Biosciences Inc., and others.

Presbyopia Therapeutics Pipeline Analysis

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company

This report comprises detailed pipeline analysis of therapeutics being developed for the treatment of presbyopia. Comprehensive insights of the pipeline phase products have been provided with special focus on strategic development activities, inclusive of collaboration and licensing information, drug designations, financing, grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the presbyopia therapeutics development. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in this report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanism of action, and drug origin with relevance to presbyopia.